You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
|
|---|---|
| Published in |
Autoimmunity Highlights, November 2017
|
| DOI | 10.1007/s13317-017-0100-y |
| Pubmed ID | |
| Authors |
Fanny Huynh Du, Elizabeth A. Mills, Yang Mao-Draayer |
| Abstract |
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine-human chimera to which many patients develop antibodies and/or experience infusion-related reactions. A second generation of anti-CD20 mAbs has been designed to be more effective, better tolerated, and of lower immunogenicity. These include the humanized versions: ocrelizumab, obinutuzumab, and veltuzumab, and the fully human, ofatumumab. We conducted a literature search of relevant randomized clinical trials in the PubMed database and ongoing trials in Clinicaltrials.gov. Most of these trials have evaluated intravenous ocrelizumab or subcutaneous ofatumumab in rheumatoid arthritis, multiple sclerosis, or systemic lupus erythematosus. Understanding how newer anti-CD20 mAbs compare with rituximab in terms of efficacy, safety, convenience, and cost is important for guiding future management of anti-CD20 mAb therapy in autoimmune diseases. |
Mendeley readers
The data shown below were compiled from readership statistics for 211 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 211 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 31 | 15% |
| Student > Ph. D. Student | 24 | 11% |
| Researcher | 23 | 11% |
| Student > Master | 17 | 8% |
| Student > Postgraduate | 12 | 6% |
| Other | 30 | 14% |
| Unknown | 74 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 17% |
| Biochemistry, Genetics and Molecular Biology | 29 | 14% |
| Immunology and Microbiology | 15 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 6% |
| Agricultural and Biological Sciences | 11 | 5% |
| Other | 32 | 15% |
| Unknown | 77 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2022.
All research outputs
#2,296,545
of 22,925,760 outputs
Outputs from Autoimmunity Highlights
#8
of 85 outputs
Outputs of similar age
#42,891
of 294,069 outputs
Outputs of similar age from Autoimmunity Highlights
#2
of 2 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 85 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.